Mounjaro (tirzepatide) is now one of the most widely prescribed weight loss medications in the UK — and it has the highest reported rate of hair loss of any GLP-1 drug on the market. Clinical trials found hair shedding in up to 5.7% of participants, and the MHRA has formally classified hair loss as a “common” side effect, affecting up to 1 in 10 users. If you’ve noticed your hair thinning since starting Mounjaro, you’re not imagining it. But understanding why it’s happening — and whether it’s likely to resolve on its own — matters more than the shedding itself.
At Hair GP, we’re seeing a growing number of women on tirzepatide who need answers about their hair. The picture isn’t always as straightforward as temporary shedding.
Why Mounjaro May Cause More Hair Loss Than Ozempic or Wegovy
Not all GLP-1 medications carry the same risk. Mounjaro is pharmacologically different from Ozempic and Wegovy — and that difference matters when it comes to your hair.
Ozempic and Wegovy both contain semaglutide, which activates GLP-1 receptors alone. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. This dual-action mechanism produces significantly greater appetite suppression and, consequently, more dramatic weight loss — averaging up to 22.5% of body weight at the highest dose. That’s among the most significant weight reduction achievable through any non-surgical intervention. For more on how semaglutide-based medications affect hair, see our pages on Ozempic hair loss and Wegovy hair loss.
The problem is straightforward: more weight loss means more physiological stress, and more physiological stress means a stronger trigger for hair shedding.
How the Three GLP-1 Medications Compare
Mounjaro’s dual-action mechanism produces more dramatic weight loss — and a higher rate of hair shedding.
| Ozempic | Wegovy | Mounjaro | |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 only | GLP-1 only | Dual GIP + GLP-1 |
| Maximum dose | 2 mg/week | 2.4 mg/week | 15 mg/week |
| Average weight loss | ~10–12% | ~15% | ~22.5% |
| Trial hair loss rate | 3–5% | 3% | 4.9–5.7% |
| MHRA hair loss classification | Not listed as common | Not listed as common | Listed as “common” |
Source: SURMOUNT clinical trial programme (tirzepatide); STEP & SUSTAIN programmes (semaglutide). MHRA product information updated 2024.
Mounjaro’s dose escalation schedule — from 2.5 mg up to 15 mg — means patients on higher doses experience greater appetite suppression and greater weight loss, placing them at higher risk of significant hair shedding.
The MHRA’s decision to classify hair loss as “common” for Mounjaro is notable. This isn’t anecdotal — it’s a regulatory conclusion based on clinical trial data. Mounjaro is currently the only GLP-1 medication to carry this classification in the UK.
If the clinical evidence shows Mounjaro carries a higher risk of hair loss than other GLP-1 medications, it’s worth understanding whether your shedding is straightforward — or whether something else is happening alongside it.
The drug itself doesn’t directly damage hair follicles. The shedding is driven by the rapid weight loss it produces, which pushes follicles into their resting phase — a condition called telogen effluvium. But for some women, the mechanism goes beyond simple TE. For a detailed explanation of how GLP-1 medications affect hair through multiple pathways, see our full guide to Ozempic and hair loss.
Is It Temporary — or Something More?
For most women, Mounjaro-related hair shedding is temporary telogen effluvium. Follicles are pushed into their resting phase by the physiological stress of rapid weight loss, and hair typically recovers within 6–12 months once weight stabilises.
But Mounjaro’s more dramatic weight loss makes it the strongest trigger in the GLP-1 class for unmasking something more significant: underlying female pattern hair loss.
Here’s why. At higher body weight, fat tissue produces oestrogen, which provides a degree of protection to hair follicles. A 22.5% reduction in body weight — significantly more than Ozempic’s 10–12% or Wegovy’s 15% — produces a correspondingly larger drop in fat-derived oestrogen. For women with a genetic predisposition to androgenetic alopecia, this hormonal shift can reveal thinning that was previously masked. The hair loss that follows isn’t temporary — it’s progressive and needs treatment.
If you’re in your 40s or 50s, perimenopause may be compounding the picture. Declining oestrogen from the menopausal transition combined with a sharp drop from rapid weight loss creates a double hit to follicle protection.
The only way to tell the difference: scalp microscopy (trichoscopy). In pure telogen effluvium, resting follicles are healthy and full-sized. In female pattern hair loss, follicles are miniaturised — producing thinner, shorter hairs with each cycle. This distinction determines whether your hair will recover on its own or requires medical treatment.
The PCOS Factor
This is where Mounjaro’s clinical picture becomes genuinely complex — and where most online advice falls short.
Mounjaro is commonly prescribed for women with PCOS and insulin resistance. These women often already have androgen-driven hair loss as a feature of their condition. Tirzepatide may improve insulin sensitivity, which can reduce androgen levels — potentially benefiting hair. But simultaneously, the weight loss it produces triggers telogen effluvium, which accelerates shedding.
The net effect depends on which mechanism dominates. Improved insulin resistance may help your PCOS-related hair loss in the long term. Rapid weight loss may worsen it in the short term. These two processes can run concurrently, and only a diagnostic assessment with trichoscopy can separate what’s temporary from what needs treatment.
If your hair hasn’t recovered 6 months after your weight has stabilised, or if the pattern of loss looks different from general shedding, a diagnostic assessment can tell you what’s actually happening.
Book a Consultation
If you're experiencing Mounjaro hair loss, a proper diagnosis is the first step toward the right treatment.
Our consultation includes a full clinical assessment, dermoscopy, and a personalised treatment plan — all in a single appointment.
Book your consultation today — £300Including assessment, and treatment plan. See full pricing
What You Can Do About Mounjaro Hair Loss
What Helps
Evidence-based approaches that address the mechanisms behind Mounjaro-related hair loss.
| Approach | Details |
|---|---|
| Protein intake | Aim for a minimum of 1.2 g/kg body weight daily. This is particularly challenging on Mounjaro’s higher doses where appetite suppression is most pronounced — conscious effort is required |
| Iron and ferritin levels | Target ferritin above 70 µg/L. The standard GP threshold of above 12 µg/L is far too low for optimal hair growth. Women on significant calorie restriction are especially vulnerable to iron deficiency |
| Comprehensive blood tests | A full panel including ferritin, vitamin D, zinc, thyroid function, and hormonal profile identifies treatable deficiencies that compound Mounjaro-related shedding |
| Medical treatment | Topical or oral minoxidil can accelerate TE recovery and treat any underlying FPHL. These are doctor-prescribed and safe alongside tirzepatide |
| Monitoring | Baseline and follow-up trichoscopy tracks whether your hair is recovering or whether FPHL is progressing — removing the guesswork |
What Won’t Help
Biotin supplements — unless you have a confirmed deficiency, which is rare. More importantly, biotin supplementation interferes with thyroid blood test results, which are particularly relevant if you’re being monitored on Mounjaro.
“Hair growth” shampoos and scalp serums. These products cannot address the internal mechanisms driving Mounjaro-related shedding. They may improve how your hair looks and feels cosmetically, but they won’t change the trajectory of the loss.
Stopping Mounjaro without medical advice. This is especially important if your Mounjaro was prescribed for type 2 diabetes — stopping affects blood sugar management, not just weight. And if the underlying cause of your hair thinning is unmasked FPHL rather than temporary TE, stopping the medication won’t resolve it. Your hair loss may continue regardless.
Mounjaro Hair Loss Treatment at Hair GP
Hair GP is a female doctor-led clinic with prescribing authority — not a trichology practice limited to topical recommendations. This matters because Mounjaro-related hair loss often requires medical treatment, not just advice.
Our approach begins with trichoscopic assessment to determine whether you’re experiencing telogen effluvium, underlying female pattern hair loss, or both. This is the critical diagnostic step that no amount of online advice can replace. We run a comprehensive blood panel with hair-specific thresholds if needed (or patients can bring along their NHS results) — ferritin above 70 µg/L, not above 12 — giving us the full nutritional and hormonal picture.
From there, we build a treatment plan that works alongside your Mounjaro. We’re not asking you to stop your medication. We’re addressing the hair loss while you continue the treatment that’s benefiting your metabolic health.
For women with PCOS, we already understand the androgen-driven component of your hair loss — and can prescribe treatments like spironolactone that target it directly. Adding Mounjaro-triggered TE into the picture makes it more complex, but it doesn’t make it more confusing — it makes a specialist assessment more important.
A 50-minute consultation with Dr Amy includes scalp microscopy, detailed examination, and a personalised treatment plan. You leave with definitive answers about what’s happening and a clear path forward.
What Patients Say
Frequently Asked Questions
Mounjaro doesn’t directly damage hair follicles. The shedding occurs because the significant weight loss it produces pushes follicles into their resting phase — a condition called telogen effluvium. Clinical trials reported hair loss in 4.9–5.7% of participants, and the MHRA now classifies it as a “common” side effect affecting up to 1 in 10 people.
The clinical data suggests yes. Mounjaro’s trial hair loss rates (4.9–5.7%) are higher than Wegovy’s (3%) and Ozempic’s (3–5%). Mounjaro is the only GLP-1 where the MHRA has formally classified hair loss as a “common” side effect. The likely reason: its dual GIP/GLP-1 mechanism produces greater average weight loss — and more dramatic weight loss is a stronger trigger for telogen effluvium.
For most women, it’s temporary — resolving within 6–12 months of weight stabilising. However, Mounjaro’s more dramatic weight loss (up to 22.5% body weight) increases the risk of unmasking underlying female pattern hair loss, which is progressive and needs treatment. A diagnostic assessment can distinguish between the two.
Not without discussing it with your prescribing doctor. This is particularly important if Mounjaro was prescribed for type 2 diabetes — stopping affects blood sugar management, not just weight. Hair shedding can usually be managed alongside the medication.
It depends. Mounjaro may improve insulin resistance, which can benefit PCOS-related androgen levels. But the weight loss it produces can simultaneously trigger telogen effluvium and potentially unmask underlying pattern hair loss. The net effect depends on which mechanism dominates — a specialist assessment with trichoscopy can separate these competing factors. Read more about PCOS and hair loss.
A comprehensive panel should include ferritin (aim above 70 µg/L — not the standard GP threshold of 12), vitamin D, zinc, full blood count, thyroid function, and hormonal profile. Women on Mounjaro’s higher doses are especially vulnerable to nutritional deficiencies from pronounced appetite suppression. Learn more about our hair loss blood tests.
Yes — Ozempic (semaglutide) works through a similar mechanism and triggers telogen effluvium. Hair loss was reported in 3–5% of clinical trial participants. Mounjaro’s rates are higher, likely because its dual mechanism produces greater weight loss.
Book a Mounjaro Hair Loss Consultation
A 50-minute consultation with Dr Amy costs £300 and includes a full scalp examination with trichoscopy, and a personalised treatment plan. You’ll leave with a clear diagnosis — whether your Mounjaro-related shedding is temporary telogen effluvium, underlying female pattern hair loss, or both — and a treatment pathway that works alongside your medication.
Understand what's causing your hair loss
A 50-minute consultation with Dr Amy includes scalp microscopy, and a personalised treatment plan—giving you definitive answers rather than continued guessing.
Book Your Hair Loss Assessment£300 consultation | Parsons Green, London
Next-day appointments often available
